Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma, Kaposi 3Lymphoproliferative Disorders 3Epstein-Barr Virus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Nasopharyngeal Carcinoma 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Head and Neck Neoplasms 1HIV Infections 1Glioblastoma 1EBV Lymphomas 1Cytomegalovirus Infections 1Castleman Disease 1Brain Neoplasms 1

Interventions

letermovir 1Zidovudine 1Valganciclovir 1Valacyclovir 1VCL-CB01 vaccine 1Blood Specimen Collection 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cytomegalovirus Infections × Valganciclovir × Clear all
NCT01972035 2022-04-12

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

University of Minnesota

Phase 2 Completed
137 enrolled 8 charts

Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡